BIT036- a likely candidate for curing COVID-19, page-23

The Deductive Reasoning

Biotron discovered in 2003 that the E Protein of the RNA virus, SARS-CoV-1, enables ion transfer that is essential for viral replication.

Biotron developed a compound, BIT036, that inhibited the ion channeling of the E Protein, and therefore stopped viral replicationin vitro.

Biotron then focused on HIV (SARS1 was finished) with same ion channel inhibiting technology in HIV, and phase 2 results created a 'vaccine-like" effect for patients.

Biotron is now testing compounds on CoV-SARS-2.

The main difference between SARS 1, and SARS2, is in the S Protein and not the E Protein.

Therefore Biotron's compounds that worked on SARS1 will work on SARS2.

(There are some independent researchers in Saudi who also think so too.)